SLC37A2 Antibody

What is SLC37A2 and why is it significant for immunological research?

SLC37A2 is a glucose-6-phosphate transporter/antiporter anchored in the endoplasmic reticulum (ER) membrane that belongs to the solute carrier family 37, which consists of four sugar-phosphate exchangers (A1, A2, A3, and A4) . It functions as an inorganic phosphate and glucose-6-phosphate antiporter, potentially transporting cytoplasmic glucose-6-phosphate into the ER lumen while translocating inorganic phosphate in the opposite direction .

Its significance lies in its high expression in immune cells, particularly macrophages and neutrophils, where it plays crucial roles in regulating inflammatory responses . Of the four SLC37 family members, SLC37A2 displays the highest transcript abundance in neutrophils and macrophages, indicating its essential role in innate immune function . Recent research has established SLC37A2 as a key negative regulator of macrophage inflammatory activation, making it an important target for immunological studies .

Based on manufacturer recommendations, optimal storage and handling of SLC37A2 antibodies involves:

• Temperature: Store at -20°C for antibodies in glycerol solutions; more sensitive preparations may require -80°C storage

• Buffer conditions: Most commercial preparations are supplied in PBS with either glycerol (typically 50%) or sodium azide (0.02%) as preservatives

• Stability: Generally stable for one year after shipment when stored properly

• Aliquoting: While some preparations state aliquoting is unnecessary for -20°C storage , it's generally recommended to minimize freeze-thaw cycles

• Working solution preparation: Dilute only the amount needed for immediate use in appropriate buffer

• Positive controls: Mouse spleen tissue lysate, thymus tissue, HeLa cells, and RAW 264.7 cells are recommended as positive controls

How do different SLC37A2 antibodies compare in detecting specific isoforms and post-translational modifications?

SLC37A2 exists in multiple isoforms generated by alternative splicing of 18 coding exons, with the longest isoform consisting of 505 amino acids . Research studies have identified specific differences in antibody performance:

Research by pan et al. demonstrated that SLC37A2 protein appears as a poorly resolved heterogeneous species with the most intense signals between 50-75 kDa in transfected cells, significantly different from the in vitro translation product of ~50 kDa . This heterogeneity is attributed to post-translational modifications, particularly N-linked glycosylation.

Advanced detection of SLC37A2 isoforms requires careful antibody selection based on the specific protein region of interest. For studies examining the functional differences between isoforms, particularly isoform 1 (which shows preference for plasma membrane) versus isoform 2 (primarily localized to tubular organelles), antibodies recognizing distinct epitopes may be necessary .

How can SLC37A2 antibodies be optimized for detecting the protein in tissues with vascular calcification?

Vascular calcification studies involving SLC37A2 require specific optimization strategies:

Sample Preparation and Fixation:

• Fresh frozen samples preserve antigenicity but may compromise morphology

• Formalin-fixed, paraffin-embedded (FFPE) tissues require optimized antigen retrieval:

  • Heat-induced epitope retrieval in citrate buffer (pH 6.0) has shown success

  • Protease treatment may improve detection in calcified tissues

Antibody Selection and Protocol Optimization:

• For immunohistochemistry of calcified aortic tissues, SLC37A2 antibodies have been used at 1:100 dilution with overnight incubation at 4°C

• Secondary detection with Histofine Simple Stain MAX-PO followed by DAB substrate development

• Von Kossa staining on serial sections helps correlate SLC37A2 expression with calcification areas

Strategic Considerations:

• Study appropriate time points in disease progression:

  • SLC37A2 mRNA expression increases in calcified aortic smooth muscle cells cultured with 2.6 mM phosphate over 14 days

  • In CKD rat models, expression changes over disease course

• Perform dual staining with cell-type specific markers:

  • Smooth muscle markers (α-SMA)

  • Macrophage markers (F4/80, CD68)

• Correlate with functional assays:

  • Runx2 expression as osteogenic marker

  • ALP activity measurements

Research by Kawada et al. demonstrated that SLC37A2 expression increases in smooth muscle cells during calcification processes . They successfully used immunostaining of aortic sections from CKD rat models, which required careful protocol optimization to simultaneously visualize both SLC37A2 and calcification markers.

What methodological approaches are recommended for investigating SLC37A2's subcellular localization?

Investigating SLC37A2's complex subcellular distribution requires sophisticated approaches:

Immunofluorescence Microscopy:

• Fixed cell immunostaining with SLC37A2 antibodies (1:100 dilution) combined with organelle markers :

  • ER markers: Protein disulfide isomerase (PDI)

  • Endo-lysosomal markers: LAMP2, Rab7, Arl8

  • Early/recycling endosomes: Vps35

  • Golgi: GM130

Live Cell Imaging:

• Fluorescent protein fusions: Both N- and C-terminal tags have been used

• Dual-color experiments with emGFP-SLC37A2 isoform 2 and mCherry-SLC37A2 isoform 1 reveal differential localization patterns

• Combine with LysoTracker Red for acidic compartment visualization

• Fluorescent substrate assays (DQ-BSA, Magic Red) for cathepsin activity co-localization

Biochemical Fractionation:

• Differential centrifugation to separate cellular compartments

• Western blotting of fractions with SLC37A2 antibodies

• Protease protection assays to determine membrane topology

Advanced Approaches:

• FRAP (Fluorescence Recovery After Photobleaching) for mobility studies

• Super-resolution microscopy (STED, STORM) for detailed structural analysis

• Immunoelectron microscopy for ultrastructural localization

Research by Pavlos et al. demonstrated that SLC37A2 localizes to an expansive network of highly dynamic tubulo-vesicular compartments in osteoclasts . Their methodology combining fixed and live-cell imaging revealed that while both SLC37A2 isoforms localized to tubular organelles, isoform 1 showed additional plasma membrane localization . These compartments were confirmed to be acidic and to house cathepsins through co-localization with LysoTracker Red and cathepsin substrates.

How should researchers resolve discrepancies in molecular weight observations when detecting SLC37A2 via Western blotting?

Researchers frequently encounter molecular weight variations when detecting SLC37A2:

Common Discrepancies:

• Predicted molecular weight: ~54-55 kDa

• Observed molecular weight: Heterogeneous 50-75 kDa species

• In vitro translation product: ~50 kDa

Resolution Strategies:

• Glycosylation Analysis:

  • Treating samples with endoglycosidases (PNGase F for N-linked glycans)

  • Observing shift to lower molecular weight confirms glycosylation

• Sample Preparation Optimization:

  • Membrane protein extraction protocols with appropriate detergents

  • Heating conditions that avoid protein aggregation

  • Complete denaturation in SDS-PAGE loading buffer

• Gel System Selection:

  • Gradient gels (4-15% or 4-20%) for better resolution of heterogeneous species

  • Tris-Tricine gels for improved resolution of membrane proteins

• Controls for Validation:

  • Include recombinant SLC37A2 protein as size reference

  • Use samples from SLC37A2 knockout models as negative controls

  • Compare with in vitro translated protein

Interpretation Framework:

Research by Kim et al. demonstrated that the discrepancy between the in vitro translation product (~50 kDa) and the heterogeneous signal in transfected cells (50-75 kDa) is attributed to post-translational modifications, particularly N-linked glycosylation . Their approach of comparing in vitro translated product with cellular expression provides a methodological framework for resolving such discrepancies.

How can SLC37A2 antibodies be utilized to study atherosclerosis progression?

SLC37A2 plays a significant role in atherosclerosis through its regulation of macrophage function:

Experimental Models:

• Hematopoietic cell-specific SLC37A2 knockout in Ldlr-/- background (bone marrow transplantation model)

• Western diet feeding for 12-16 weeks to induce hyperlipidemia and atherosclerosis

Analytical Approaches:

• Tissue Analysis:

  • Aortic root sections for atherosclerotic plaque quantification

  • Immunohistochemistry with SLC37A2 antibodies (1:100 dilution) to assess expression patterns in plaques

  • Co-staining with macrophage markers (F4/80, CD68) and M1/M2 markers

• Cellular Studies:

  • Analysis of macrophage polarization in atherosclerotic lesions

  • Assessment of efferocytosis capacity and inflammatory cytokine production

  • Correlation with lipid loading and foam cell formation

• Plasma Analysis:

  • Lipid profiles (total cholesterol, triglycerides, HDL, LDL)

  • Inflammatory cytokines, particularly IL-10

  • Correlation between plasma IL-10 levels and plaque size

Key Research Findings:

Studies by Zheng et al. demonstrated that hematopoietic cell-specific SLC37A2 deletion in Ldlr-/- mice increased plasma lipid concentrations after Western diet feeding and resulted in more extensive atherosclerosis compared to controls . Importantly, aortic root intimal area was inversely correlated with plasma IL-10 levels but not total cholesterol, suggesting inflammation rather than plasma cholesterol was responsible for increased atherosclerosis in these mice .

The research revealed that SLC37A2 deficiency impaired apoptotic cell-induced glycolysis, subsequently attenuating IL-10 production . This suggests that SLC37A2 expression is required to support alternative macrophage activation both in vitro and in vivo, with significant implications for atherosclerosis progression.

How can researchers optimize antibody-based detection methods for studying SLC37A2 in tissues with high background or low expression?

Detecting SLC37A2 in challenging tissues requires specialized optimization approaches:

Sample Preparation Strategies:

• Fresh frozen tissues preserve antigenicity but may show higher background

• For FFPE tissues, optimize fixation time (12-24h) and use neutral buffered formalin

• Test multiple antigen retrieval methods (heat-induced with citrate or EDTA buffers at varying pH)

Signal Enhancement Methods:

• Tyramide signal amplification (TSA) can increase sensitivity 10-100 fold

• Polymer-based detection systems (e.g., EnVision, ImmPRESS) offer improved signal without increased background

• Biotin-free detection systems avoid endogenous biotin interference

Background Reduction Techniques:

Protocol Optimization:

• Titrate primary antibody (starting with 1:50-1:200 range)

• Test extended incubation times (overnight at 4°C)

• Use appropriate controls:

  • Tissues from SLC37A2 knockout animals

  • Competing peptide controls

  • Isotype control antibodies

Multi-label Strategies:

• Sequential staining with careful antibody stripping between rounds

• Multiplexed immunofluorescence with spectral unmixing

• Cyclic immunofluorescence for co-expression studies

For tissues with very low expression, combining in situ hybridization for SLC37A2 mRNA with antibody detection of the protein can provide validation and increased sensitivity for expression studies.

What approaches should researchers use to quantify changes in SLC37A2 expression during macrophage polarization and inflammatory responses?

Accurate quantification of SLC37A2 dynamics during macrophage activation requires multi-modal approaches:

Protein Expression Analysis:

• Western Blotting:

  • Normalize to stable housekeeping proteins (GAPDH, β-actin)

  • Account for heterogeneous migration pattern (50-75 kDa range)

  • Employ densitometry with total signal integration across heterogeneous bands

  • Use SLC37A2 knockout controls for band specificity verification

• Flow Cytometry:

  • Permeabilization protocols optimized for ER membrane proteins

  • Multi-parameter analysis with polarization markers

  • Mean fluorescence intensity quantification

• Quantitative Microscopy:

  • Immunofluorescence with standardized acquisition parameters

  • Integrated density measurements

  • Colocalization coefficients with organelle markers

Transcript Quantification:

• RT-qPCR:

  • Primers: human SLC37A2, 5'-TCACTTTAGTGCCAAGGAGGC-3' and 5'-CCATTGGTGTAGTCAGAGACG-3'

  • Normalization to stable reference genes (GAPDH)

  • Relative quantification using ΔΔCt method

• RNA-Seq:

  • Whole transcriptome analysis during polarization

  • Time-course studies during inflammatory activation

  • Integration with other metabolic and inflammatory gene modules

Experimental Design Considerations:

• Polarization protocols:

  • M1 polarization: LPS (100 ng/mL) + IFN-γ (20 ng/mL)

  • M2 polarization: IL-4 (20 ng/mL) or IL-13 (20 ng/mL)

  • Time course analysis (2, 6, 12, 24, 48h)

• Baseline comparisons:

  • Unstimulated macrophages (M0)

  • Different tissue origins (bone marrow vs. peritoneal vs. alveolar)

  • Species differences (human vs. mouse)

• Response validation:

  • M1 markers: TNF, IL-6, IL-1β, iNOS

  • M2 markers: Arg1, Mrc1, IL-10

Research by Wang et al. showed that LPS rapidly increases macrophage SLC37A2 protein expression, with levels remaining high at 3-6h and declining at 24-48h . Their approach of combining protein expression analysis with functional readouts provides a comprehensive framework for studying SLC37A2 dynamics during inflammatory responses.